

SEQUENCE LISTING

<110> Johnson & Johnson Research Pty Ltd
 <120> A means of producing and utilising a population of disease
 specific cytotoxic T lymphocytes
 <130> 02 1355 7401
 <160> 9
 <170> PatentIn version 3.3

<210> 1
 <211> 17
 <212> RNA
 <213> Human immunodeficiency virus type 1
 <400> 1
 ggagccagua gauccua 17

<210> 2
 <211> 17
 <212> RNA
 <213> Human immunodeficiency virus type 1
 <400> 2
 ggagccagua gauccua 17

<210> 3
 <211> 38
 <212> DNA
 <213> Artificial
 <220>
 <223> Rz2 ribozyme sequence
 <400> 3
 ttaggatcct gatgagtccg tgaggacgaa actggctc 38

<210> 4
 <211> 9
 <212> PRT
 <213> Homo sapiens
 <400> 4

Ile Leu Lys Glu Pro Val His Gly Val

1 5

<210> 5

<211> 9

<212> PRT

<213> Homo sapiens

<400> 5

Ser Leu Tyr Asn Thr Val Ala Thr Leu

1 5

<210> 6

<211> 12

<212> PRT

<213> Artificial

<220>

<223> CD8 peptide

<400> 6

Ala Ala Glu Gly Leu Asp Thr Gln Arg Phe Ser Gly

1 5 10

<210> 7

<211> 41

<212> DNA

<213> Artificial

<220>

<223> Sub G5-FD

<220>

<221> misc_binding

<222> (15)..(15)

<223> FAM moiety attached

<220>

<221> misc_binding

<222> (24)..(24)

<223> DABCYL moiety attached

<400> 7

caccaaaaga gaactgcaat guttcaggac ccacaggagc g 41

<210> 8

<211> 21

<212> DNA

<213> Artificial

<220>

<223> 5L1A primer

<400> 8

gagttctacc ggcagtgcaa a 21

<210> 9

<211> 76

<212> DNA

<213> Artificial

<220>

<223> 3L1Dz5 primer

<400> 9

caccaaaaga gaactgcaat tcgttgtagc tagcctttca ggaccacag gagcggcaag 60

caattcggtc tgtatc 76